Want to see ZSTK full AI Analyst Report?
Top Page
ZeroStack
(NASDAQ:ZSTK)
Select Model
Select Model
Rating:48Neutral
Price Target:
$6.00
▲(313.79% Upside)
Action:Reiterated
Date:08/21/26
The score is mainly constrained by weak financial performance (sharp revenue decline, negative gross profit, very large losses, and ongoing cash burn). Technicals provide some support with the stock trading above key moving averages and positive MACD, but the very high RSI suggests overbought risk. Valuation is also pressured by unprofitability and no dividend, while recent corporate actions are modestly supportive but introduce dilution concerns.
Positive Factors
Private Cloud Infrastructure Focus
Software for on-premises private clouds targets enterprises seeking cloud-like control on their own hardware. This addresses durable hybrid and sovereign infrastructure needs, although the pack provides no proof of current adoption or competitive advantage.
Negative Factors
Sharp Revenue Contraction
A severe revenue decline indicates meaningful demand, execution, or channel disruption. Sustained contraction would reduce operating leverage, weaken the company’s ability to absorb fixed costs, and make a durable return to profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Private Cloud Infrastructure Focus
Software for on-premises private clouds targets enterprises seeking cloud-like control on their own hardware. This addresses durable hybrid and sovereign infrastructure needs, although the pack provides no proof of current adoption or competitive advantage.
Read all positive factors
ZeroStack (ZSTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$103.02M
Dividend YieldN/A
Average Volume (3M)79.92K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth-23.56%
EPS Growth-249.27%
CountryUS
Employees21
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-120.27
Shares Outstanding17,489,828
10 Day Avg. Volume25,949
30 Day Avg. Volume79,922
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.48
P/FCF Ratio-1.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$29.50M
ZeroStack Business Overview & Revenue Model
Company Description
ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods ...
How the Company Makes Money
null...
ZeroStack Earnings Call Summary
Earnings Call Date:Nov 13, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic expansions and leadership changes that position Flora Growth for future growth in both the U.S. and European markets. However, the company faced challenges with declining revenue and increased operating expenses. Despite these challenges, the substantial reduction in net loss and strong performance of key brands suggest a cautiously optimistic outlook.Positive Updates
Strategic Expansion in the U.S. and Germany
Flora Growth is leveraging its brands, JustCBD and Vessel, to capture market share in the U.S. with a focus on the growing infused beverage market. In Germany, the company is launching a Parallel Import business to meet the demand for affordable pharmaceuticals.
Negative Updates
Decline in Revenue
Revenues for Q3 2024 were $12.5 million, down from $17.3 million in Q3 2023. Revenue for the first nine months of 2024 was $46.2 million, compared to $58.1 million for the same period in 2023.
Read all updates
Q3-2024 Updates
Positive
Negative
Strategic Expansion in the U.S. and Germany
Flora Growth is leveraging its brands, JustCBD and Vessel, to capture market share in the U.S. with a focus on the growing infused beverage market. In Germany, the company is launching a Parallel Import business to meet the demand for affordable pharmaceuticals.
Read all positive updates
Company Guidance
During the Flora Growth Corporation Q3 2024 earnings call, the company provided guidance reflecting strategic initiatives and financial metrics. Flora's revenues for the third quarter of 2024 were $12.5 million, down from $17.3 million in the same quarter of 2023, primarily due to discontinuing unprofitable lines. The company reported a net loss of $9.8 million, a significant improvement from the $47.3 million loss in the prior year. Total operating expenses increased to $6.5 million compared to $5.5 million in Q3 2023. JustCBD maintained a gross profit margin of 40% on $4.2 million in sales, while Vessel achieved a 55% margin on $1.1 million in sales. Parallel Import business and regulatory advancements in the U.S. and Germany are seen as key drivers for future growth. The company ended the quarter with $4.2 million in cash and $21.3 million in current assets, including $7.9 million in saleable inventory. Flora is optimistic about leveraging federal rescheduling in the U.S. and regulatory developments in Germany to enhance market presence.ZeroStack Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.03M | 35.68M | 59.51M | 76.07M | 33.40M | 8.98M |
| Gross Profit | -3.91M | -4.82M | 12.50M | 17.74M | 13.25M | 2.42M |
| EBITDA | -6.64M | -8.98M | -15.10M | -45.87M | -17.87M | -20.93M |
| Net Income | -177.84M | -120.85M | -15.91M | -57.04M | -52.41M | -21.25M |
Balance Sheet | ||||||
| Total Assets | 25.19M | 130.24M | 26.23M | 23.63M | 80.99M | 85.48M |
| Cash, Cash Equivalents and Short-Term Investments | 2.96M | 5.62M | 6.02M | 4.35M | 8.94M | 37.61M |
| Total Debt | 2.76M | 53.93M | 4.90M | 3.67M | 3.76M | 1.34M |
| Total Liabilities | 11.37M | 59.68M | 21.72M | 17.22M | 24.57M | 8.54M |
| Stockholders Equity | 13.82M | 70.55M | 4.51M | 6.40M | 56.82M | 77.17M |
Cash Flow | ||||||
| Free Cash Flow | -5.64M | -8.80M | -5.17M | -8.56M | -17.23M | -24.63M |
| Operating Cash Flow | -5.60M | -8.68M | -5.03M | -8.40M | -15.94M | -20.65M |
| Investing Cash Flow | -2.75M | -3.46M | 203.00K | -234.00K | -15.80M | -14.55M |
| Financing Cash Flow | 9.68M | 11.35M | 6.49M | 3.15M | 4.41M | 58.11M |
ZeroStack Technical Analysis
Positive
1.45
Price Trends
2.69
Positive
4.02
Positive
6.04
Negative
Market Momentum
0.49
Negative
67.97
Neutral
33.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZSTK, the sentiment is Positive. The current price of 1.45 is below the 20-day moving average (MA) of 2.21, below the 50-day MA of 2.69, and below the 200-day MA of 6.04, indicating a neutral trend. The MACD of 0.49 indicates Negative momentum. The RSI at 67.97 is Neutral, neither overbought nor oversold. The STOCH value of 33.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZSTK.
ZeroStack Risk Analysis
ZeroStack disclosed 67 risk factors in its most recent earnings report. ZeroStack reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ZeroStack Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
48 Neutral | $103.02M | -0.04 | -382.27% | ― | -23.56% | -249.27% | |
45 Neutral | $43.31M | -1.59 | -92.47% | ― | -100.00% | 54.21% | |
44 Neutral | $5.66M | -1.66 | -33.59% | ― | 10.01% | 95.01% | |
44 Neutral | $21.39M | -0.34 | -96.48% | ― | 33.82% | 34.05% | |
38 Underperform | $1.03M | -1,062.50 | -3.03% | ― | -11.91% | -285.23% |
* Financial Sector Average
ZSTK
ZeroStack
4.71
-16.51
-77.80%
YCBD
cbdMD
0.51
-0.16
-24.18%
SXTC
China SXT Pharmaceuticals
4.10
-18,835.90
-99.98%
COSM
Cosmos Holdings
0.22
-0.62
-73.72%
IMCC
IM Cannabis Corp
0.11
-2.20
-95.15%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.57
-14.07
-79.76%
ZeroStack Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
ZeroStack Completes Strategic Crypto Asset Acquisition Financing
Positive
Jul 23, 2026
On July 20, 2026, ZeroStack Corp. closed a previously announced private cryptocurrency financing after shareholders approved a continuance proposal at the 2026 Annual and Special Meeting. Investors contributed 142,232,948 native tokens of the Zero...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
ZeroStack Shareholders Back Governance and Equity Plan Changes
Positive
Jul 20, 2026
ZeroStack Corp. held its 2026 Annual and Special Meeting of Shareholders on July 20, 2026, where investors approved amendments to the 2022 Incentive Compensation Plan that doubled the common shares and incentive stock options available and formall...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.